biostudies-literatureUnknown6(1)Eilts SK<h4>Importance</h4>One of the biggest challenges when using anti-vascular endothelial growth factor (VEGF) agents to treat retinopathy of prematurity (ROP) is the need to perform long-term follow-up examinations to identify eyes at risk of ROP reactivation requiring retreatment.<h4>Objective</h4>To evaluate whether an artificial intelligence (AI)-based vascular severity score (VSS) can be used to analyze ROP regression and reactivation after anti-VEGF treatment and potentially identify eyes at risk of ROP reactivation requiring retreatment.<h4>Design, setting, and participants</h4>This prognostic study was a secondary analysis of posterior pole fundus images collected during the multicenter, double-blind, investigator-initiated Comparing Alternative Ranibizumab Dosages for Safety and EfficJAMA network opene2251512https://www.ebi.ac.uk/biostudies/studies/S-EPMC9857423biostudies-literatureAssessment of Retinopathy of Prematurity Regression and Reactivation Using an Artificial Intelligence-Based Vascular Severity Score.PMC9857423Tautz JStech MSabir HClemens CRSmith LEHLehmann FWegener STekaat MGoebel AWerner CFriedhoff CRoider JOberacher-Velten IAckermann PKonrad JFelzmann SHerrmann KJandeck ITode JBuhler AStavropolou DSupe JAisenbrey SBruckmann ABergmann AEhmer AGerding HHentschel RKrohne TUBrinken RPetrak MSzymanek BBraunstein JBusch MCampbell JPCzauderna JKopetzky EHorn SStahl ANentwich MHasselbach HCPurtskhvanidze KSchrader SBarth THofmann MDralle WRudolph GSchrader MHornig-Franz IHohn TBlecha CSegerer HMihailovic NCoyner ASSchwarz SReiff CUhlig CMonig TGenzel-Boroviczeny OAvenarius SMuller-Hansen IKleinert EKittel JVolker MKant EBrinkmann CKGerberth ALohmeier KTermuhlen JEilts SKAltmann MFalkenau SLindemann SRieger-Fackeldey EKeller-Wackerbauer ASchroder GMuller PSchroder MAdorf AHagemann UHelbig HDaniel MSchmidt SKalpathy-Cramer JSchuart CHolz FGEhrt OOstmo SLoos DSBenga JApel CBottger RHufendiek KJagle HSusskind DReichl SPartsch MChiang MFMuller AMuller CPressler AEter NLagreze WAComparing Alternative Ranibizumab Dosages for Safety and Efficacy in Retinopathy of Prematurity (CARE-ROP) Study GroupBendiks MChan RVPBialkowski AGliem MAlten FGrundel MMolnar FRichter OLagreze WKunze DAlex AThilmany CRaffel YGuthoff TPfeil JMHeymer PModlich SMayatepek ESchmitz-Valckenberg SKupitz DGuthoff RSchmitz EJOckert-Schon FDimopoulos SGross NBrunder MCBrevis FInhoffen WBartsch KBrandl-Ruhle SMeltendorf SPoschkamp BSteinberg JMunch HGfalseAssessment of Retinopathy of Prematurity Regression and Reactivation Using an Artificial Intelligence-Based Vascular Severity Score.<h4>Importance</h4>One of the biggest challenges when using anti-vascular endothelial growth factor (VEGF) agents to treat retinopathy of prematurity (ROP) is the need to perform long-term follow-up examinations to identify eyes at risk of ROP reactivation requiring retreatment.<h4>Objective</h4>To evaluate whether an artificial intelligence (AI)-based vascular severity score (VSS) can be used to analyze ROP regression and reactivation after anti-VEGF treatment and potentially identify eyes at risk of ROP reactivation requiring retreatment.<h4>Design, setting, and participants</h4>This prognostic study was a secondary analysis of posterior pole fundus images collected during the multicenter, double-blind, investigator-initiated Comparing Alternative Ranibizumab Dosages for Safety and Effic2023-01-01T00:00:00Z2023 Jan2025-04-26T12:54:53.957Z2025-04-06T14:07:35.349ZS-EPMC98574233665657810.1001/jamanetworkopen.2022.51512